Study of FYU-981 in Hyperuricemia With or Without Gout
Status:
Completed
Trial end date:
2018-10-24
Target enrollment:
Participant gender:
Summary
The purpose of this study is confirmatory investigation of safety and efficacy of FYU-981
administered orally to hyperuricemic patients with and without gout for 34 or 58 weeks by the
method of multicenter, open label and ascending dose regimen.